Palladium Partners’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | $6.53M | Sell |
40,261
-1,090
| -3% | -$158K | 0.29% | 83 |
|
|
2021
Q4 | $5.6M | Buy |
41,351
+1,149
| +3% | +$136K | 0.23% | 87 |
|
|
2021
Q3 | $4.34M | Buy |
40,202
+176
| +0.4% | +$20.1K | 0.2% | 94 |
|
|
2021
Q2 | $4.51M | Sell |
40,026
-1,122
| -3% | -$126K | 0.21% | 89 |
|
|
2021
Q1 | $4.45M | Sell |
41,148
-758
| -2% | -$81.1K | 0.22% | 88 |
|
|
2020
Q4 | $4.49M | Sell |
41,906
-2,169
| -5% | -$208K | 0.25% | 81 |
|
|
2020
Q3 | $3.86M | Sell |
44,075
-2,629
| -6% | -$248K | 0.24% | 86 |
|
|
2020
Q2 | $4.59M | Sell |
46,704
-706
| -1% | -$62.2K | 0.31% | 79 |
|
|
2020
Q1 | $3.61M | Sell |
47,410
-8,160
| -15% | -$695K | 0.3% | 81 |
|
|
2019
Q4 | $4.92M | Sell |
55,570
-67,171
| -55% | -$5.58M | 0.32% | 84 |
|
|
2019
Q3 | $11.6M | Buy |
122,741
+56,937
| +87% | +$3.9M | 0.81% | 37 |
|
|
2019
Q2 | $4.79M | Sell |
65,804
-10,804
| -14% | -$849K | 0.33% | 82 |
|
|
2019
Q1 | $6.17M | Sell |
76,608
-51,032
| -40% | -$4.17M | 0.44% | 67 |
|
|
2018
Q4 | $11.8M | Buy |
127,640
+4,272
| +3% | +$376K | 0.94% | 33 |
|
|
2018
Q3 | $11.7M | Buy |
123,368
+2,448
| +2% | +$232K | 0.79% | 37 |
|
|
2018
Q2 | $11.2M | Sell |
120,920
-17,164
| -12% | -$1.68M | 0.81% | 36 |
|
|
2018
Q1 | $13.1M | Sell |
138,084
-1,864
| -1% | -$205K | 0.97% | 31 |
|
|
2017
Q4 | $13.5M | Sell |
139,948
-54
| -0% | -$5.09K | 0.98% | 34 |
|
|
2017
Q3 | $12.4M | Sell |
140,002
-4
| -0% | -$304 | 0.95% | 32 |
|
|
2017
Q2 | $10.2M | Buy |
140,006
+1,434
| +1% | +$96.4K | 0.8% | 40 |
|
|
2017
Q1 | $9.03M | Buy |
138,572
+4,195
| +3% | +$264K | 0.73% | 43 |
|
|
2016
Q4 | $8.41M | Buy |
134,377
+80,559
| +150% | +$4.92M | 0.71% | 44 |
|
|
2016
Q3 | $3.4M | Sell |
53,818
-537
| -1% | -$34.8K | 0.3% | 82 |
|
|
2016
Q2 | $3.37M | Sell |
54,355
-1,198
| -2% | -$73K | 0.31% | 80 |
|
|
2016
Q1 | $3.17M | Buy |
55,553
+1,455
| +3% | +$81.1K | 0.29% | 82 |
|
|
2015
Q4 | $3.21M | Buy |
54,098
+1,765
| +3% | +$102K | 0.3% | 83 |
|
|
2015
Q3 | $2.85M | Sell |
52,333
-275
| -0.5% | -$17.9K | 0.28% | 85 |
|
|
2015
Q2 | $3.54M | Sell |
52,608
-817
| -2% | -$53.3K | 0.32% | 85 |
|
|
2015
Q1 | $3.13M | Sell |
53,425
-825
| -2% | -$49.8K | 0.27% | 98 |
|
|
2014
Q4 | $3.55M | Sell |
54,250
-1,260
| -2% | -$79.4K | 0.31% | 91 |
|
|
2014
Q3 | $3.21M | Buy |
55,510
+75
| +0.1% | +$4.16K | 0.29% | 88 |
|
|
2014
Q2 | $3.13M | Buy |
55,435
+375
| +0.7% | +$19.7K | 0.28% | 91 |
|
|
2014
Q1 | $2.83M | Sell |
55,060
-200
| -0.4% | -$10.1K | 0.26% | 93 |
|
|
2013
Q4 | $2.92M | Sell |
55,260
-700
| -1% | -$34.4K | 0.28% | 97 |
|
|
2013
Q3 | $2.5M | Sell |
55,960
-1,550
| -3% | -$68.7K | 0.25% | 101 |
|
|
2013
Q2 | $2.38M | Buy |
+57,510
| New | +$2.52M | 0.25% | 104 |
|
Other funds holding ABBV
Palladium Partners's ABBV Position: Q1 2022 in Review
Palladium Partners reduced its AbbVie (ABBV) stake by 2.6% in Q1 2022, selling an estimated $158K and leaving 40,261 shares worth $6.53M. The position accounts for 0.29% of the portfolio, ranked #83.
Palladium Partners first reported a position in ABBV in Q2 2013 and has held it in 36 quarters since. The position peaked at $13.5M in Q4 2017. 3,053 funds tracked by Wall St. Rank hold ABBV as of Q1 2022.
- Palladium Partners held 40,261 shares of AbbVie worth $6.53M as of Q1 2022.
- Palladium Partners sold 1,090 AbbVie shares in Q1 2022, an estimated $158K.
- AbbVie made up 0.29% of Palladium Partners's portfolio in Q1 2022, its #83 holding.
- Palladium Partners first reported a position in AbbVie in Q2 2013 and has held it in 36 quarters since.
- Palladium Partners's AbbVie position peaked at $13.5M in Q4 2017.
- 3,053 funds tracked by Wall St. Rank held AbbVie as of Q1 2022.
Based on Palladium Partners's 13F filing for Q1 2022, filed 26 Apr 2022.